Article Sidebar

PDF
Date Published: 27/06/2023
Abstract Views: 1309
Views PDF: 0
Views PDF: 621
DOI: https://doi.org/10.51298/vmj.v527i1B.5759
Issue
Vol. 527 No. 1B (2023)
Section
Các bài báo
How to Cite
Nguyễn, T. T. T., Đỗ, V. D., Phạm, M. H., Bùi, M. T., Nguyễn, C. T., & Lê, D. Q. (2023). COST-EFFECTIVENESS ANALYSIS OF SACUBITRIL/VALSARTAN VERSUS ACEI IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN VIETNAM. Vietnam Medical Journal, 527(1B). https://doi.org/10.51298/vmj.v527i1B.5759

COST-EFFECTIVENESS ANALYSIS OF SACUBITRIL/VALSARTAN VERSUS ACEI IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN VIETNAM

Thị Thu Thủy Nguyễn1,, Văn Dũng Đỗ2, Mạnh Hùng Phạm3, Minh Trạng Bùi4, Chí Thanh Nguyễn4, Diễm Quỳnh Lê5
1 HIU
2 University of Medicine and Pharmacy at Ho Chi Minh City
3 Cardiovascular Institute – Bach Mai Hospital
4 CMI
5 HTARI

Main Article Content

Abstract

Objectives: Cost-effectiveness analysis of sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors (ACEIs) for treatment of heart failure with reduced ejection fraction (HFrEF) in Vietnam. Research methods: Modeling using Markov model for cost-effectiveness analysis in payer perspective. Collecting input parameters using systematic review, retrospective health insurance payment data at hospitals in Ha Noi and Ho Chi Minh city, and consultation of clinical experts. Results: Sacubitril/valsartan resulted in an increase of 0.50 QALY and 0.59 LYG compared to ACEIs; and increase total costs by 65.8 to 74.4 million VND. Incremental cost-effectiveness ratio (ICER) for sacubitril/valsartan ranged from 132.7 to 149.6 million VND/QALY compared to ACEIs. Mortality rate and quality of life coefficient most influence on the ICER value and the probability that sacubitril/valsartan is cost-effective compared to enalapril in the treatment of HFrEF is 90%. Conclusion: From payer perspective, with the 1-3 times GDP-per-capita willingness-to-pay threshold, sacubitril/valsartan is cost-effective compared to ACEIs in the treatment of HFrEF.

Article Details

Keywords

Sacubitril/valsartan, ACEI, HFrEF, cost-effectiveness

References

1. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. New England Journal of Medicine. 2009;360(14):1418-28.
2. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). The American journal of cardiology. 2008;101(7):1016-22. doi: 10.1016/ j.amjcard.2007.11.061
3. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
4. World Health O, Baltussen RMPM, Adam T, Tan-Torres Edejer T, Hutubessy RCW, Acharya A, et al. Making choices in health : WHO guide to cost-effectiveness analysis / edited by T. Tan-Torres Edejer ... [et al]. Geneva: World Health Organization; 2003.
5. Ademi Z, Pfeil AM, Hancock E, Trueman D, Haroun RH, Deschaseaux C, et al. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction. Swiss Med Wkly. 2017;147:w14533. doi:10.4414/smw.2017.14533
6. Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, et al. Cost-effectiveness Analysis of Sacubitril/ Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiol. 2016; 1(6):666-72. doi:10.1001/ jamacardio.2016.1747
7. Park S-K, Hong S-H, Kim H, Kim S, Lee E-K. Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea. Clinical therapeutics. 2019; 41(6):1066-79.
8. Ahn SA, Jong P, Yusuf S, Bangdiwala SI, Pouleur HG, Rousseau MF. Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial. Journal of the American College of Cardiology. 2006; 47(9):1904-5.
9. Berg J, Lindgren P, Mejhert M, Edner M, Dahlström U, Kahan T. Determinants of utility based on the EuroQol five-dimensional questionnaire in patients with chronic heart failure and their change over time: results from the swedish heart failure registry. Value in Health. 2015;18(4):439-48.
10. Griffiths A, Paracha N, Davies A, Branscombe N, Cowie M, Sculpher M. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Heart. 2014; 100 (13):1031-6.